Navigation Links
Long-term L-carnitine supplementation prevents development of liver cancer
Date:3/24/2009

A study will be published on March 21, 2009 in World Journal of Gastroenterology addresses the question. A research group in King Saud University, Kingdom of Saudi Arabia investigated, for the first time, the role of carnitine, a naturally occurring compound that is synthesized mainly in the liver, during the development of hepatocarcinogenesis. Authors of the study reported that carnitine deficiency is a risk factor and should be viewed as a mechanism in hepatic carcinogenesis, and that long-term L-carnitine supplementation prevents the development of liver cancer. Therefore, carnitine supplementation alone or in combination with other natural chemopreventive compounds could be used to prevent, slow or reverse the occurrence of liver cancer.

Chemoprevention is defined as the use of naturally occurring and/or synthetic compounds in cancer therapy in which the occurrence of cancer can be entirely prevented, slowed or reversed. L-carnitine is a naturally occurring compound which is primarily located in mitochondria and possesses potential protective effects against many mitochondrial toxic agents. It is derived from two sources; endogenous synthesis, in the liver and kidney, and from exogenous dietary sources such as red meat and dairy products. L-carnitine is an essential cofactor for the translocation of long chain fatty acids from the cytoplasmic compartment into mitochondria, where beta-oxidation enzymes are located for ATP production. Despite the liver being the main organ responsible for endogenous synthesis of L-carnitine, we were unable to find any studies investigating the role of long-term endogenous carnitine depletion and/or carnitine deficiency during induction of hepatic carcinogenesis.

The research team by Professor Sayed-Ahmed from College of Pharmacy, King Saud University used an experimental model of hepatocarcinogenesis under conditions of carnitine depletion and carnitine supplementation.

In the carnitine-depleted rat model, there were a progressive increase in the activities of liver enzymes as well as massive degenerative changes and evidence of pre-neoplastic lesions in liver tissues including clusters of hepatocytes with atypia and an increased proliferative rate, diffuse bridging fibrosis and nodule formation, bile ducts with marked reactive atypia showing nuclear enlargement, high nuclear/cytoplasmic ratio and prominent nucleoli. Interestingly, L-carnitine supplementation resulted in a complete reversal of the increase in liver enzymes compared to normal values, as well as normal liver histology with unremarkable central vein and no evidence of pre-neoplastic lesions in liver tissues.

Due to the fact that liver cancer is one of the major health problems in the world and a large sector of patients seek medical attention at a relatively late stage which increases the cost of treatment, King Saud University granted Prof. Sayed-Ahmed and his colleagues a research project with the following specific aims: (1) to understand the possible molecular mechanisms whereby carnitine deficiency provokes hepatic carcinogenesis. (2) to understand the relationship between hepatic cancer and its resistance to cancer chemotherapy, and (3) to gain knowledge on the possible mechanisms by which carnitine supplementation alone or in combination with other natural chemopreventive compounds could be used to prevent, slow or reverse the occurrence of liver cancer.


'/>"/>

Contact: Lin Tian
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. John Hancock #1 in Long-Term Care Insurance Industry Sales in 2008
2. Studies show children can complete treatment for peanut allergies and achieve long-term tolerance
3. Global Leader in Information Technology Services and Business Solutions Signs Long-Term Agreement with PureWellness
4. Frost & Sullivan Recognizes ValveXchanges Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages
5. Almost 30% of Long-Term Care is Financed Out-of-Pocket, Report Finds
6. Prudential Long-Term Care Product Simplifies Decisions
7. Long-term outlook good for rotator cuff repairs
8. Goserelin improves long-term survival in premenopausal women with early breast cancer
9. Infection prevention falls short in Canadian long-term care facilities
10. Location, Location, Location: Cost of Long-Term Care Services Vary Widely by Region
11. BMP Sunstone Reiterates Commitment to Quality, Innovation and Long-Term Growth at Meeting with Senior Officials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... 2017 , ... Guide to FDA and EU Medical Device Regulations: 2017 Edition, ... of the Atlantic devicemakers do business, this fully updated and expanded guide keeps them ... to the full text of the FDA’s regulations in 21 CFR Parts 800 to ...
(Date:6/28/2017)... ... ... David B. Sosin, a founding partner at the law firm Sosin, Arnold ... President for the Illinois State Bar Association , in accordance with the organization’s rules ... 2016 following a state-wide election and served in that capacity for the past year prior ...
(Date:6/28/2017)... Columbia (PRWEB) , ... June 28, 2017 , ... ... (FSE: ZEON) is pleased to announce that a two year study conducted by ... Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a ...
(Date:6/28/2017)... ... June 28, 2017 , ... The Dianne ... the greater Cincinnati metropolitan area, is teaming up with the local chapter of ... children receiving treatment in nearby hospitals. , Ronald McDonald House of Greater Cincinnati, ...
(Date:6/27/2017)... ... 27, 2017 , ... Harbour , a DAO (decentralized autonomous organization) that ... has released their technical specifications . , 2017 has seen an explosion of ... for determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ) today ... R. Goodwin , U.S. District Court Judge for the ... entered a case management order in MDL 2325, American ... (the "MDL") that includes a provision requiring plaintiffs in ... specific causation within one hundred twenty (120) days of ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences ... Company specializing in the development of cannabinoid-based drugs, ... a company overview at three upcoming scientific and ... Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: